ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.
B7-H1 Antigen
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Chemokine CCL2
/ genetics
Gene Expression Regulation, Neoplastic
/ immunology
Glioblastoma
/ genetics
Humans
MAP Kinase Signaling System
/ genetics
Macrophages
/ immunology
Programmed Cell Death 1 Ligand 2 Protein
/ genetics
Proteomics
Receptors, G-Protein-Coupled
/ genetics
Transcriptome
/ genetics
Tumor Microenvironment
/ immunology
CCL2/MCP1
ERK1/2
Glioblastoma
Immune checkpoints
The Cancer Genome Atlas
Tumour-associated macrophages
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
30 09 2019
30 09 2019
Historique:
received:
10
05
2019
revised:
02
08
2019
accepted:
09
08
2019
pubmed:
31
8
2019
medline:
20
9
2020
entrez:
31
8
2019
Statut:
epublish
Résumé
The tumor microenvironment is an important determinant of glioblastoma (GBM) progression and response to treatment. How oncogenic signaling in GBM cells modulates the composition of the tumor microenvironment and its activation is unclear. We aimed to explore the potential local immunoregulatory function of ERK1/2 signaling in GBM. Using proteomic and transcriptomic data (RNA seq) available for GBM tumors from The Cancer Genome Atlas (TCGA), we show that GBM with high levels of phosphorylated ERK1/2 have increased infiltration of tumor-associated macrophages (TAM) with a non-inflammatory M2 polarization. Using three human GBM cell lines in culture, we confirmed the existence of ERK1/2-dependent regulation of the production of the macrophage chemoattractant CCL2/MCP1. In contrast with this positive regulation of TAM recruitment, we found no evidence of a direct effect of ERK1/2 signaling on two other important aspects of TAM regulation by GBM cells: (1) the expression of the immune checkpoint ligands PD-L1 and PD-L2, expressed at high mRNA levels in GBM compared with other solid tumors; (2) the production of the tumor metabolite lactate recently reported to dampen tumor immunity by interacting with the receptor GPR65 present on the surface of TAM. Taken together, our observations suggest that ERK1/2 signaling regulates the recruitment of TAM in the GBM microenvironment. These findings highlight some potentially important particularities of the immune microenvironment in GBM and could provide an explanation for the recent observation that GBM with activated ERK1/2 signaling may respond better to anti-PD1 therapeutics.
Identifiants
pubmed: 31467175
pii: BSR20191433
doi: 10.1042/BSR20191433
pmc: PMC6744584
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
CCL2 protein, human
0
CD274 protein, human
0
Chemokine CCL2
0
GPR65 protein, human
0
PDCD1LG2 protein, human
0
Programmed Cell Death 1 Ligand 2 Protein
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2019 The Author(s).
Références
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Cell Rep. 2017 Apr 4;19(1):101-113
pubmed: 28380350
Expert Rev Neurother. 2018 Sep;18(9):729-737
pubmed: 30099909
Immunity. 2016 Mar 15;44(3):609-621
pubmed: 26944201
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Emerg Top Life Sci. 2017 Dec 12;1(5):429-445
pubmed: 33525803
Oncotarget. 2017 Oct 6;8(53):91779-91794
pubmed: 29207684
Cell. 2018 Oct 4;175(2):313-326
pubmed: 30290139
Int J Cancer. 2012 Dec 15;131(12):2961-9
pubmed: 22514082
Nat Med. 2019 Mar;25(3):462-469
pubmed: 30742119
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Nat Immunol. 2018 Dec;19(12):1319-1329
pubmed: 30397348
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Trends Cancer. 2018 Dec;4(12):802-809
pubmed: 30470302
Cancer Cell. 2016 Apr 11;29(4):563-573
pubmed: 27070703
J Neuropathol Exp Neurol. 2017 Oct 1;76(10):838-847
pubmed: 28922853
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Discov Med. 2015 Jun;19(107):471-7
pubmed: 26175405
Trends Cancer. 2019 Mar;5(3):149-156
pubmed: 30898262
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nat Med. 2019 Mar;25(3):389-402
pubmed: 30842677
Biochim Biophys Acta Gen Subj. 2018 Apr;1862(4):999-1005
pubmed: 29413908
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Am J Cancer Res. 2016 Aug 01;6(8):1599-608
pubmed: 27648352
Nat Immunol. 2018 Dec;19(12):1281-1283
pubmed: 30397351
Oncogene. 1998 Jul 2;16(26):3435-43
pubmed: 9692551
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Int J Cancer. 2018 Jan 15;142(2):381-391
pubmed: 28921565